Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phio Pharmaceuticals Corp. - Common Stock (NQ: PHIO )

1.760 +0.020 (+1.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 348,384
Open 1.650
Bid (Size) 1.660 (13)
Ask (Size) 1.840 (23)
Prev. Close 1.740
Today's Range 1.570 - 1.810
52wk Range 1.530 - 10.35
Shares Outstanding 1,055,219
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Regulatory
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company that develops... 
Via Newsfile

Performance

YTD
-74.59%
-74.59%
1 Month
-26.05%
-26.05%
3 Month
-50.00%
-50.00%
6 Month
-71.45%
-71.45%
1 Year
-74.56%
-74.56%

More News

Read More
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology
Via Newsfile
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
Via Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
Via Newsfile
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Via Newsfile
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Via Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Via Newsfile
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
Via Newsfile
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
Via Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
Via Newsfile
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
Via Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
Via Newsfile
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
PHIO Stock Earnings: Phio Pharma Misses EPS for Q2 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.